Hepatitis C Antiviral Resistance in African-Americans
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the hypothesis that African-Americans respond less well to
combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have
chronic hepatitis C genotype 1 and who were not previously treated with either interferon or
ribavirin. Reasons for differences in response, regardless of race, will be studied.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
Hoffmann-La Roche National Cancer Institute (NCI) National Center for Advancing Translational Science (NCATS) National Institute on Minority Health and Health Disparities (NIMHD)